| Nov 15 |
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
|
| Nov 14 |
UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
|
| Nov 14 |
Crinetics Pharmaceuticals Third Quarter 2024 Earnings: US$0.96 loss per share (vs US$1.01 loss in 3Q 2023)
|
| Nov 13 |
Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
|
| Nov 13 |
Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2024 Earnings Call Transcript
|
| Nov 12 |
Crinetics Pharmaceuticals GAAP EPS of -$0.96 misses by $0.05
|
| Nov 12 |
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
|
| Nov 12 |
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Nov 12 |
Earnings Scheduled For November 12, 2024
|
| Nov 11 |
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
